FDA’s Endocrinologic and Metabolic Drugs Advisory Committee
Executive Summary
Will meet March 26-27 in Conference Rooms D & E, Parklawn Building, Rockville, Maryland. On March 26 at 9 a.m., the committee will discuss treatment of precocious puberty with LHRH analogs (NDAs for Takeda-Abbott's luprolide and Ortho's histrelin). On the second day, beginning at 8 a.m., discussion will focus on alleged occurrence of hypoglycemia awareness in diabetics treated with human insulin.